All Stories

  1. ANKHD1 promotes pathogenic proliferation in Autosomal Dominant Polycystic Kidney Disease via the Cyclin D1/CDK4 pathway
  2. Polycystin-1 acts as an atypical adhesion GPCR that responds to novel Wnt signaling and mechanical stimuli
  3. Drug and siRNA screens identify ROCK2 as a therapeutic target for ciliopathies
  4. Clinical Spectrum and Prognosis of Atypical Autosomal Dominant Polycystic Kidney Disease Caused by Monoallelic Pathogenic Variants of IFT140
  5. Insights from ADPedKD, ERKReg and RaDaR registries provide a multi-national perspective on the presentation of childhood autosomal dominant polycystic kidney disease in high- and middle-income countries
  6. Rare disease gene association discovery in the 100,000 Genomes Project
  7. Commentary: Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) - an update
  8. KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
  9. KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary
  10. MT41 The Diagnostic Accuracy of Ultrasound and Genetic Tests for the Diagnosis of Autosomal Dominant Polycystic Kidney Disease: A Systematic Mapping Review
  11. BICC1 Interacts with PKD1 and PKD2 to Drive Cystogenesis in ADPKD
  12. Description and Cross-Sectional Analyses of 25,880 Adults and Children in the UK National Registry of Rare Kidney Diseases Cohort
  13. Corrigendum to “An Artificial Intelligence Generated Automated Algorithm to Measure Total Kidney Volume in ADPKD” [Kidney International Reports Volume 9, Issue 2, February 2024, Pages 249-256]
  14. #2613 Clinical spectrum and prognosis of the atypical polycystic kidney disease caused by monoallelic loss-of-function IFT140 variants
  15. #2695 A Polycystin-1-Bicaudal C1 complex regulates focal adhesion function through integrin beta-1, F-actin organisation and local translation in HKE cells
  16. Chronic kidney disease and the global public health agenda: an international consensus
  17. Clinical Characteristics and Kidney Outcomes in Chinese Patients with Autosomal Dominant Polycystic Kidney Disease
  18. Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort
  19. HYDROchlorothiazide versus placebo to PROTECT polycystic kidney disease patients and improve their quality of life: study protocol and rationale for the HYDRO-PROTECT randomized controlled trial
  20. An Artificial Intelligence Generated Automated Algorithm to Measure Total Kidney Volume in ADPKD
  21. Global analysis of urinary extracellular vesicle small RNAs in autosomal dominant polycystic kidney disease
  22. Combining genotype with height-adjusted kidney length predicts rapid progression of ADPKD
  23. Macrophage subpopulation identity in Drosophila is modulated by apoptotic cell clearance and related signalling pathways
  24. Liver transplant recipients with polycystic liver disease have longer waiting times but better long-term clinical outcomes than those with liver disease due to other causes: A retrospective cross-sectional study
  25. Rare disease gene association discovery from burden analysis of the 100,000 Genomes Project data
  26. Macrophage subpopulation identity inDrosophilais modulated by apoptotic cell clearance and related signalling pathways
  27. Identification of renal cyst cells of type I Nephronophthisis by single-nucleus RNA sequencing
  28. The Common PKD1 p.(Ile3167Phe) Variant Is Hypomorphic and Associated with Very Early Onset, Biallelic Polycystic Kidney Disease
  29. Barriers and facilitators to the implementation of guidelines in rare diseases: a systematic review
  30. OVERTURE: A Worldwide, Prospective, Observational Study of Disease Characteristics in Patients With ADPKD
  31. Patient Perspectives on ADPKD
  32. Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial
  33. Hypertension in young adults with autosomal dominant polycystic kidney disease: a case for early screening?
  34. The association of urinary epidermal growth factors with ADPKD disease severity and progression
  35. Diet and Polycystic Kidney Disease: Nutrients, Foods, Dietary Patterns, and Implications for Practice
  36. WCN23-0391 THE CLINICAL CHARACTERISTICS AND KIDNEY OUTCOME IN CHINESE PATIENTS WITH TYPICAL AND ATYPICAL POLYCYSTIC KIDNEY DISEASE
  37. Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association
  38. Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association
  39. The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKD
  40. P73 Patients with polycystic liver disease have longer waiting times but better clinical outcomes following liver transplantation in the UK
  41. A founderUMODvariant is a common cause of hereditary nephropathy in the British population
  42. Regional variation in tolvaptan prescribing across England: national data and retrospective evaluation from an expert centre
  43. Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association
  44. Patients with polcystic liver disease have longer waiting times but better clinical outcomes following liver transplantation in the UK
  45. Barriers and facilitators to the implementation of guidelines in rare diseases: A systematic review
  46. Flank pain has a significant adverse impact on quality of life in ADPKD: the CYSTic-QoL study
  47. Research priorities for autosomal dominant polycystic kidney disease: a UK priority setting partnership
  48. An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease I...
  49. FC029: A Multivariate Model Identifies Genotype, Hypertension and Kidney Length as Independent Baseline Predictors of Disease Progression in a Longitudinal Autosomal Dominant Polycystic Kidney Disease Patient Cohort
  50. MO012: Development of an Accurate Automated Segmentation Algorithm to Measure Total Kidney Volume in ADPKD Suitable for Clinical Application (The Cystvas Study)
  51. MO015: The Interaction of Gender and Genotype in the Development of Polycystic Liver Disease in ADPKD
  52. MO030: Familial clustering of a rare UMOD variant in undiagnosed hereditary nephropathy suggests the presence of a common ancestral founder mutation
  53. Can ketogenic dietary interventions slow disease progression in ADPKD: what we know and what we don't
  54. From WEDA to EDTA to ERA: 60 years of supporting European nephrology and counting
  55. Individualized everolimus treatment for tuberous sclerosis-related angiomyolipoma promotes treatment adherence and response
  56. Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype
  57. Metformin induces lactate accumulation and accelerates renal cyst progression in Pkd1-deficient mice
  58. An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease I...
  59. TAMEing ADPKD with metformin: safe and effective?
  60. An Nphp1 knockout mouse model targeting exon 2–20 demonstrates characteristic phenotypes of human nephronophthisis
  61. MO023FLANK PAIN HAS A MAJOR NEGATIVE IMPACT ON HEALTH-RELATED QUALITY OF LIFE IN ADPKD: THE CYSTIC I STUDY
  62. Biallelic inheritance of hypomorphic PKD1 variants is highly prevalent in very early onset polycystic kidney disease
  63. Drug repurposing in autosomal dominant polycystic kidney disease: back to the future with pioglitazone
  64. Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrology–Polycystic Kidney Disease (SONG-PKD) Consensus Workshop
  65. An international cohort study of autosomal dominant tubulointerstitial kidney disease due to mutations identifies distinct clinical subtypes
  66. Coronavirus-associated kidney outcomes in COVID-19, SARS, and MERS: a meta-analysis and systematic review
  67. The Controversial Role of Fibrosis in Autosomal Dominant Polycystic Kidney Disease
  68. ‘A sword of Damocles’: patient and caregiver beliefs, attitudes and perspectives on presymptomatic testing for autosomal dominant polycystic kidney disease: a focus group study
  69. STAGED-PKD: An Enriched, Seamless, Two-Stage Study for Venglustat Assessment in ADPKD
  70. STAGED-PKD: Patient Enrichment and Modeling-Driven Efficient ADPKD Trial Design
  71. Core Outcome Domains for Trials in Autosomal Dominant Polycystic Kidney Disease: An International Delphi Survey
  72. Polycystin-1 regulates ARHGAP35-dependent centrosomal RhoA activation and ROCK signaling
  73. Clinical spectrum, prognosis and estimated prevalence of DNAJB11-kidney disease
  74. Global microRNA profiling in human urinary exosomes reveals novel disease biomarkers and cellular pathways for autosomal dominant polycystic kidney disease
  75. Post-translational modifications of the polycystin proteins
  76. Range and Variability of Outcomes Reported in Randomized Trials Conducted in Patients With Polycystic Kidney Disease: A Systematic Review
  77. The positive effect of selective prostaglandin E2 receptor EP2 and EP4 blockade on cystogenesis in vitro is counteracted by increased kidney inflammation in vivo
  78. Publisher Correction: Whole-genome sequencing of a sporadic primary immunodeficiency cohort
  79. Cellular signaling in PKD: foreword
  80. SO092REDUCED QUALITY OF LIFE IN ADPKD PATIENTS WITH CKD STAGE 1-3: THE CYSTIC I QUALITY OF LIFE STUDY
  81. Whole-genome sequencing of a sporadic primary immunodeficiency cohort
  82. Ankhd1 enhances polycystic kidney disease development via promoting proliferation and fibrosis
  83. SAT-442 Identification of Exosome MicroRNAs as Novel Biomarkers for Rapid Disease Progression in Autosomal Dominant Polycystic Kidney Disease
  84. Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease
  85. A high throughput zebrafish chemical screen reveals ALK5 and non-canonical androgen signalling as modulators of the pkd2−/− phenotype
  86. Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis
  87. Tuberous Sclerosis Complex (TSC): Expert Recommendations for Provision of Coordinated Care
  88. SAT-100 “A SWORD OF DAMOCLES”: PATIENT AND CAREGIVER BELIEFS, ATTITUDES AND PERSPECTIVES ON GENETIC SCREENING AND TESTING FOR AUTOSOMAL POLYCYSTIC KIDNEY DISEASE - FOCUS GROUP STUDY
  89. SAT-334 GENETIC TESTING OF FAMILIES WITH VERY EARLY ONSET POLYCYSTIC KIDNEY DISEASE REVEALS THE FUNCTIONAL SIGNIFICANCE OF HYPOMORPHIC VARIANTS
  90. Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases
  91. FO026GLOBAL MICRORNA PROFILING IN HUMAN URINARY EXOSOMES REVEALS NEW DISEASE BIOMARKERS AND CELLULAR PATHWAYS FOR AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
  92. SaO005CLINICAL PRESENTATION AND PROGNOSIS OF DNAJB11-ASSOCIATED NEPHROPATHY: AN INTERNATIONAL COLLABORATIVE STUDY
  93. Renal monocyte chemoattractant protein-1: an emerging universal biomarker and therapeutic target for kidney diseases?
  94. Identifying patient‐important outcomes in polycystic kidney disease: An international nominal group technique study
  95. Imaging of Kidney Cysts and Cystic Kidney Diseases in Children: An International Working Group Consensus Statement
  96. A rapid high-performance semi-automated tool to measure total kidney volume from MRI in autosomal dominant polycystic kidney disease
  97. Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop
  98. Imaging of kidney cysts and cystic kidney diseases in children. Consensus paper by an ad hoc committee
  99. Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA
  100. Linear and Nonlinear Estimated GFR Slopes in ADPKD Patients Reaching ESRD
  101. A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model
  102. Tolvaptan slows disease progression in late-stage ADPKD
  103. European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care
  104. Standardised Outcomes in Nephrology—Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease
  105. Targeting new cellular disease pathways in autosomal dominant polycystic kidney disease
  106. Targeting new cellular disease pathways in autosomal dominant polycystic kidney disease
  107. The Sorting Nexin 3 Retromer Pathway Regulates the Cell Surface Localization and Activity of a Wnt-Activated Polycystin Channel Complex
  108. Making sense of polycystic kidney disease
  109. TO033VERY EARLY-ONSET AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE DUE TO BI-ALLELIC MUTATIONS IN PKD1 AND PKD2
  110. Parallel microarray profiling identifies ErbB4 as a determinant of cyst growth in ADPKD and a prognostic biomarker for disease progression
  111. STAT5 drives abnormal proliferation in autosomal dominant polycystic kidney disease
  112. Development of a rapid semi-automated tool to measure total kidney volume in autosomal dominant polycystic kidney disease
  113. Autosomal dominant polycystic kidney disease: recent advances in clinical management
  114. SO052DEVELOPMENT OF A RAPID SEMI-AUTOMATED TOOL TO MEASURE TOTAL KIDNEY VOLUME IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
  115. SO053SELECTIVE PROSTAGLANDIN E2 RECEPTOR BLOCKADE FOR THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
  116. The Cyclic AMP Signaling Pathway and Direct PKA Phosphorylation Regulate Polycystin-2 (TRPP2) Channel Function
  117. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice
  118. New onset diabetes after kidney transplantation in patients with autosomal dominant polycystic kidney disease: systematic review protocol: Figure 1
  119. A polycystin-centric view of cyst formation and disease: the polycystins revisited
  120. Autosomal dominant polycystic kidney disease
  121. Autosomal dominant polycystic kidney disease
  122. The cAMP Signaling Pathway and Direct Protein Kinase A Phosphorylation Regulate Polycystin-2 (TRPP2) Channel Function
  123. The Polycystin-1, Lipoxygenase, and α-Toxin Domain Regulates Polycystin-1 Trafficking
  124. Increased psychosocial risk, depression and reduced quality of life living with autosomal dominant polycystic kidney disease
  125. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
  126. Department of Error
  127. Backbone assignment and secondary structure of the PLAT domain of human polycystin-1
  128. Autosomal dominant polycystic kidney disease: the changing face of clinical management
  129. FP064ASSESSING THE LONG TERM OUTCOMES OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) USING THE ADPKD OUTCOMES MODEL: A UK CASE STUDY
  130. FP364INCREASED PSYCHOSOCIAL BURDEN AND ADVERSE QUALITY OF LIFE IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
  131. Genetic Testing in the Assessment of Living Related Kidney Donors at Risk of Autosomal Dominant Polycystic Kidney Disease
  132. SuO042POLYCYSTIN-1 TRAFFICKING IS REGULATED BY CAMP DEPENDENT PHOSPHORYLATION OF THE PLAT DOMAIN
  133. Endothelin and Tubulointerstitial Renal Disease
  134. Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease
  135. Erratum
  136. Development Of A Model To Predict Disease Progression In Autosomal Dominant Polycystic Kidney Disease (ADPKD)
  137. Genetics and Genomics of Chronic Kidney Disease
  138. Building a network of ADPKD reference centres across Europe: the EuroCYST initiative
  139. How simple are 'simple renal cysts'?
  140. Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry
  141. Sudden death due to subarachnoid haemorrhage in an infant with autosomal dominant polycystic kidney disease
  142. Rare inherited kidney diseases: challenges, opportunities, and perspectives
  143. RENAL DEVELOPMENT AND CYSTIC DISEASES
  144. Metabolic abnormalities in autosomal dominant polycystic kidney disease
  145. Angiopoietin-1 regulates microvascular reactivity and protects the microcirculation during acute endothelial dysfunction: Role of eNOS and VE-cadherin
  146. TRPP2 in Polycystic Kidney Disease
  147. Polycystin-1 but not polycystin-2 deficiency causes upregulation of the mTOR pathway and can be synergistically targeted with rapamycin and metformin
  148. Cosegregation of Focal Segmental Glomerulosclerosis in a Family with Familial Partial Lipodystrophy due to a Mutation in <b><i>LMNA</i></b>
  149. New treatments for autosomal dominant polycystic kidney disease
  150. Fabrication of Luminescent Monolayered Tungsten Dichalcogenides Quantum Dots with Giant Spin-Valley Coupling
  151. The Role of Phospholipase D in Modulating the MTOR Signaling Pathway in Polycystic Kidney Disease
  152. Primary cilia and renal cysts: does length matter?
  153. Fabrication and Luminescence of Monolayered Boron Nitride Quantum Dots
  154. The natural history of autosomal dominant polycystic kidney disease: 30-year experience from a single centre
  155. Hyperphosphorylation of polycystin-2 at a critical residue in disease reveals an essential role for polycystin-1-regulated dephosphorylation
  156. Pkd2 mesenteric vessels exhibit a primary defect in endothelium-dependent vasodilatation restored by rosiglitazone
  157. Cystic kidney diseases: many ways to form a cyst
  158. The ERA-EDTA Working Group on inherited kidney disorders
  159. Mechanism-Based Therapeutics for Autosomal Dominant Polycystic Kidney Disease: Recent Progress and Future Prospects
  160. 32 PKD2 mutant zebrafish display excessive developmental angiogenesis
  161. Spurious hypophosphatemia associated with monoclonal paraproteinemia
  162. Thiazolidinediones inhibit MDCK cyst growth through disrupting oriented cell division and apicobasal polarity
  163. A Single Amino Acid Residue Constitutes the Third Dimerization Domain Essential for the Assembly and Function of the Tetrameric Polycystin-2 (TRPP2) Channel
  164. What’s new in… Ciliopathies
  165. Endothelin in Polycystic Kidney Disease
  166. Protein Kinase D–mediated Phosphorylation of Polycystin-2 (TRPP2) Is Essential for Its Effects on Cell Growth and Calcium Channel Activity
  167. Towards the Integration of Genetic Knowledge into Clinical Practice
  168. A polycystin-2 (TRPP2) dimerization domain essential for the function of heteromeric polycystin complexes
  169. Structural and Molecular Basis of the Assembly of the TRPP2/PKD1 Complex
  170. Screening for intracranial aneurysms in ADPKD
  171. Pkd2 Dosage Influences Cellular Repair Responses following Ischemia-Reperfusion Injury
  172. Screening for intracranial aneurysms in ADPKD
  173. Structural and molecular basis of the assembly of the TRPP2/PKD1 complex
  174. A novel dephosphorylation‐activated conductance in a mouse renal collecting duct cell line
  175. Peroxisome Proliferator-Activated Receptor Gamma Agonists in Kidney Disease – Future Promise, Present Fears
  176. Autosomal dominant polycystic kidney disease
  177. Homophilic and heterophilic polycystin 1 interactions regulate E-cadherin recruitment and junction assembly in MDCK cells
  178. Homophilic and heterophilic polycystin 1 interactions regulate E-cadherin recruitment and junction assembly in MDCK cells
  179. Identification and Functional Characterization of an N-terminal Oligomerization Domain for Polycystin-2
  180. Activation of TRPP2 through mDia1-dependent voltage gating
  181. Chronic Renal Disease
  182. Autosomal Dominant Polycystic Kidney Disease: Recent Advances in Pathogenesis and Treatment
  183. Hyperproliferation of PKD1 cystic cells is induced by insulin-like growth factor-1 activation of the Ras/Raf signalling system
  184. Involvement of Hypoxia-Inducible Transcription Factors in Polycystic Kidney Disease
  185. Endothelin B Receptor Blockade Accelerates Disease Progression in a Murine Model of Autosomal Dominant Polycystic Kidney Disease
  186. Contributors
  187. Polycystic Kidney Disease Is a Risk Factor for New-Onset Diabetes After Transplantation
  188. Functional characterization of GATA3 mutations causing the hypoparathyroidism-deafness-renal (HDR) dysplasia syndrome: insight into mechanisms of DNA binding by the GATA3 transcription factor
  189. Haploinsufficiency of Pkd2 is associated with increased tubular cell proliferation and interstitial fibrosis in two murine Pkd2 models
  190. Identification of an N-terminal glycogen synthase kinase 3 phosphorylation site which regulates the functional localization of polycystin-2 in vivo and in vitro
  191. Detection of Proximal Tubular Motile Cilia in a Patient With Renal Sarcoidosis Associated With Hypercalcemia
  192. Molecular pathogenesis of ADPKD: The polycystin complex gets complex
  193. Expression and Cellular Localisation of Renal Endothelin-1 and Endothelin Receptor Subtypes in Autosomal-Dominant Polycystic Kidney Disease
  194. Aberrant Polycystin-1 Expression Results in Modification of Activator Protein-1 Activity, whereas Wnt Signaling Remains Unaffected
  195. Functional Analysis of PKD1 Transgenic Lines Reveals a Direct Role for Polycystin-1 in Mediating Cell-Cell Adhesion
  196. Association of mutation position in polycystic kidney disease 1 (PKD1) gene and development of a vascular phenotype
  197. Genetic Renal Abnormalities
  198. Polycystic kidney disease—the ciliary connection
  199. Polycystin-2 expression is increased following experimental ischaemic renal injury
  200. Identification, Characterization, and Localization of a Novel Kidney Polycystin-1-Polycystin-2 Complex
  201. Polycystin Expression in the Kidney and Other Tissues: Complexity, Consensus and Controversy
  202. Endothelin antagonists in renal disease
  203. Polycystin-1 expression in PKD1, early-onset PKD1, and TSC2/PKD1 cystic tissue
  204. Coordinate Expression of the Autosomal Dominant Polycystic Kidney Disease Proteins, Polycystin-2 And Polycystin-1, in Normal and Cystic Tissue
  205. The Renal Association
  206. Cyst formation in ADPKD: new insights from natural and targeted mutants
  207. Regional Variations in Endothelin-1 and its Receptor Subtypes in Human Coronary Vasculature: Pathophysiological Implications in Coronary Disease
  208. Identification of Mutations in the Duplicated Region of the Polycystic Kidney Disease 1 Gene (PKD1) by a Novel Approach
  209. Molecular basis of renal cyst formation—one hit or two?
  210. A stable, nonsense mutation associated with a case of infantile onset polycystic kidney disease 1 (PKD1)
  211. Polycystin, the polycystic kidney disease 1 protein, is expressed by epithelial cells in fetal, adult, and polycystic kidney.
  212. Candidate 56 and 58 kDa protein(s) responsible for mediating the renal defects in oncogenic hypophosphatemic osteomalacia
  213. Tubulointerstitial actions of endothelins in the kidney: roles in health and disease
  214. Tubulointerstitial actions of endothelins in the kidney: roles in health and disease
  215. An endothelin-1 mediated autocrine growth loop involved in human renal tubular regeneration
  216. Oncogenous hypophosphataemic osteomalacia: effects on phosphate transport and vitamin D metabolism in cultured human kidney cells
  217. Human high density lipoproteins stimulate endothelin-1 release by cultured human renal proximal tubular cells
  218. Tubular lipidosis: Epiphenomenon or pathogenetic lesion in human renal disease?
  219. Loss of glomerular function and tubulointerstitial fibrosis:Cause or effect?
  220. Tubular-Derived Growth Factors and Cytokines in the Pathogenesis of Tubulointerstitial Fibrosis: Implications for Human Renal Disease Progression
  221. Tubular-derived cytokines and human renal disease progression
  222. Mechanisms of tubulo‐interstitiaI injury in progressive renal diseases
  223. Effect of cyclosporin A on endothelin synthesis by cultured human renal cortical epithelial cells
  224. Tuberculous peritonitis complicating peritoneal dialysis: a case for early diagnostic laparotomy?
  225. Sinus arrest and asystole due to severe lithium intoxication
  226. The pathogenesis of the ovarian hyperstimulation syndrome (OHS): a possible role for ovarian renin
  227. Atrial natriuretic peptide release responds to atrial stretch and not to atrial pressure: observations during pericardiocentesis in a young woman
  228. The Use of Lithium Clearance in Bartter's Syndrome
  229. Intermittent absorption of warfarin caused by an unrecognized pharyngeal pouch
  230. Effects of noradrenaline infusion on platelet catecholamine levels and platelet aggregation
  231. Hypersensitivity vasculitis complicating intravenous streptokinase therapy in acute myocardial infarction